loading
Ventyx Biosciences Inc stock is traded at $1.06, with a volume of 1.77M. It is down -0.93% in the last 24 hours and down -32.91% over the past month.
See More
Previous Close:
$1.07
Open:
$1.09
24h Volume:
1.77M
Relative Volume:
1.43
Market Cap:
$76.11M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.3212
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
-13.11%
1M Performance:
-32.91%
6M Performance:
-49.76%
1Y Performance:
-79.77%
1-Day Range:
Value
$1.03
$1.115
1-Week Range:
Value
$1.03
$1.27
52-Week Range:
Value
$1.03
$5.66

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
Name
Ventyx Biosciences Inc
Name
Phone
(858) 945-2393
Name
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
VTYX's Discussions on Twitter

Compare VTYX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VTYX
Ventyx Biosciences Inc
1.06 76.11M 0 -192.96M -167.04M -3.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-12-24 Upgrade Oppenheimer Perform → Outperform
Mar-12-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-07-23 Downgrade H.C. Wainwright Buy → Neutral
Nov-07-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-07-23 Downgrade Oppenheimer Outperform → Perform
Nov-07-23 Downgrade Stifel Buy → Hold
Nov-07-23 Downgrade Wells Fargo Overweight → Equal Weight
Jun-14-23 Resumed Credit Suisse Outperform
Mar-21-23 Initiated Wells Fargo Overweight
Dec-19-22 Initiated Goldman Buy
Nov-17-22 Initiated Morgan Stanley Overweight
Sep-07-22 Initiated Stifel Buy
Sep-01-22 Initiated H.C. Wainwright Buy
May-09-22 Initiated Credit Suisse Outperform
Mar-31-22 Initiated Canaccord Genuity Buy
Feb-01-22 Initiated Oppenheimer Outperform
Nov-15-21 Initiated Jefferies Buy
Nov-15-21 Initiated Piper Sandler Overweight
View All

Ventyx Biosciences Inc Stock (VTYX) Latest News

pulisher
Apr 02, 2025

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Ventyx boosts advisory board with top scientists By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Ventyx boosts advisory board with top scientists - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts - GlobeNewswire

Apr 01, 2025
pulisher
Mar 31, 2025

Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value - simplywall.st

Mar 31, 2025
pulisher
Mar 28, 2025

Ventyx Biosciences stock hits 52-week low at $1.21 amid market challenges - Investing.com

Mar 28, 2025
pulisher
Mar 21, 2025

Ventyx Biosciences stock hits 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 21, 2025
pulisher
Mar 15, 2025

Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - MSN

Mar 15, 2025
pulisher
Mar 11, 2025

Ventyx Biosciences stock hits 52-week low at $1.37 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Acquires 40,813 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Ventyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights – VTYX - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Ventyx Biosciences Reports 2024 Financial Results and Progress - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTYX - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 02, 2025

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm - ACCESS Newswire

Mar 02, 2025
pulisher
Feb 28, 2025

Ventyx Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Ventyx Biosciences reports Q4 EPS (41c), consensus (55c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

VTYXVentyx Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan

Feb 27, 2025
pulisher
Feb 27, 2025

Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Ventyx Biosciences Reports Fourth Quarter and Full Year - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Can Ventyx's $252.9M Cash Cushion and 3 Upcoming Trial Readouts Excite Biotech Investors? - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress - Yahoo Finance

Feb 27, 2025
pulisher
Feb 24, 2025

Ventyx Biosciences stock hits 52-week low at $1.57 By Investing.com - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

Ventyx Biosciences stock hits 52-week low at $1.57 - Investing.com India

Feb 24, 2025
pulisher
Feb 23, 2025

Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 23, 2025

Ventyx Biosciences (VTYX) to Release Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire

Feb 21, 2025
pulisher
Feb 21, 2025

Ventyx Biosciences Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

Feb 21, 2025
pulisher
Feb 19, 2025

VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire

Feb 19, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences Announces Presentation of Data from the - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx reports mixed results in Crohn's disease trial By Investing.com - Investing.com Australia

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx reports mixed results in Crohn's disease trial - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 - The Bakersfield Californian

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 - Yahoo Finance

Feb 18, 2025
pulisher
Feb 15, 2025

SG Americas Securities LLC Cuts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Feb 15, 2025
pulisher
Feb 13, 2025

RSLS stock touches 52-week low at $2.57 amid market challenges - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Ventyx Biosciences Inc (NASDAQ: VTYX): Overvalued In Comparison To Others? - Stocks Register

Feb 13, 2025

Ventyx Biosciences Inc Stock (VTYX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):